Click Here to return To Results

 

An Open-Label Trial of Combination Therapy With Interferon B-1a and Oral Methotrexate in MS Neurol 58:314-317, Calabresi,P.A.,et al, 2002 See this aricle in Pubmed Article Abstract An open-label study was performed to evaluate the safety and efficacy of combination therapy with weekly oral methotrexate (20 mg) and interferon B-1a (IFNB-1a) in 15 patients with MS who had experienced exacerbations while receiving IFNB mo notherapy. Nausea was the only major side effect. A 44% reduction in the number of gadolinium-enhanced lesions seen on MRI scan was observed during combination therapy (p = 0.02). There was a trend toward fewer exacerbations. This combination therapy appears to be safe and well tolerated, and should be studied in a controlled trial.

Related Tags

(click to filter results - removes previous filter) immunosuppressive agents interferon interferon beta 1-a methotrexate MRI MRI,abnormal MRI,contrast enhanced multiple sclerosis multiple sclerosis,treatment of treatment of neurologic disorder

Click Here to return To Results